- Home
- OTLK vs RAPT Comparison
OTLK vs RAPT Comparison
Compare OTLK & RAPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OTLK
- RAPT
- Stock Information
- Founded
- OTLK 2010
- RAPT 2015
- Country
- OTLK United States
- RAPT United States
- Employees
- OTLK N/A
- RAPT N/A
- Industry
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- RAPT Biotechnology: Pharmaceutical Preparations
- Sector
- OTLK Health Care
- RAPT Health Care
- Exchange
- OTLK Nasdaq
- RAPT Nasdaq
- Market Cap
- OTLK 56.3M
- RAPT 59.1M
- IPO Year
- OTLK 2016
- RAPT 2019
- Fundamental
- Price
- OTLK $1.48
- RAPT $1.23
- Analyst Decision
- OTLK Strong Buy
- RAPT Hold
- Analyst Count
- OTLK 5
- RAPT 7
- Target Price
- OTLK $10.20
- RAPT $5.00
- AVG Volume (30 Days)
- OTLK 479.6K
- RAPT 442.4K
- Earning Date
- OTLK 02-14-2025
- RAPT 03-06-2025
- Dividend Yield
- OTLK N/A
- RAPT N/A
- EPS Growth
- OTLK N/A
- RAPT N/A
- EPS
- OTLK N/A
- RAPT N/A
- Revenue
- OTLK N/A
- RAPT N/A
- Revenue This Year
- OTLK N/A
- RAPT N/A
- Revenue Next Year
- OTLK $288.46
- RAPT N/A
- P/E Ratio
- OTLK N/A
- RAPT N/A
- Revenue Growth
- OTLK N/A
- RAPT N/A
- 52 Week Low
- OTLK $0.87
- RAPT $0.79
- 52 Week High
- OTLK $12.85
- RAPT $9.65
- Technical
- Relative Strength Index (RSI)
- OTLK 40.05
- RAPT 47.31
- Support Level
- OTLK $1.38
- RAPT $1.04
- Resistance Level
- OTLK $1.51
- RAPT $1.18
- Average True Range (ATR)
- OTLK 0.12
- RAPT 0.09
- MACD
- OTLK 0.02
- RAPT 0.00
- Stochastic Oscillator
- OTLK 38.86
- RAPT 36.67
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
About RAPT RAPT Therapeutics Inc.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.